Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Dr Susan O’Brien from MD Anderson Cancer Center, Houston, Texas, USA, chairs an interesting and stimulating symposium sponsored by Mundipharm International on issues affecting the management of CLL held during the 15th International Workshop on Chronic Lymphocytic Leukaemia – iwCLL – in September 2013.
With the numerous major advances that have been made in CLL over the past few years come opportunities and challenges for patients and health care professionals. These opportunities include improved PFS and OS; these challenges include which agents to select and how, which agents to use in combination, how to manage older/frail patients and how to pay for these newer therapies. All these issues are addressed in this symposium by three international experts and a lively panel discussion that answers questions from the packed audience.
Content taken from a Mundipharma sponsored satellite symposium at iwCLL 2013 as part of the official programme.
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
The evolving paradigm in management of Multiple Myeloma